

QUARTERLY NEWSLETTER: SEPTEMBER 2024

Spotlight on patient safety

Empowering teams for safe clinical care

In this issue:

World patient safety day 2

Micromedex enhancements 2

New mobile app
Drug monograph navigation enhancements
IV Compatibility updates
Expanded pediatric content
RED BOOK updates
and more

News you can use 6

6 ways Micromedex supports patient safety
Training resources
Take the clinical challenge

Upcoming activities 7



Tackling medication errors:

[The global challenge of preventing medication-related harm for safer care](#)



Hot topic:

[Microdosing chocolate bars and the critical role of poison centers in protecting public health](#)



Patient safety insights:

[Considerations for polypharmacy and avoidable harm in elderly patients](#)

Micromedex marks world patient safety day

World Patient Safety Day on September 17th calls for global action to protect patients and promote safe care practices. In this edition, we spotlight patient safety, featuring articles on [reducing medication-related harm](#), [preventing avoidable harm in vulnerable populations](#), and [safeguarding public health against emerging threats](#).

Clinicians are committed to delivering safe, effective care, and today's complex healthcare landscape presents significant challenges. Clinical decision support is crucial in navigating these complexities, and Micromedex is committed to enhancing patient safety. In this newsletter, we highlight recent and upcoming Micromedex enhancements designed to support our users with the tools they need to provide safe, effective care.

Enhancements to the Micromedex solutions you use every day

Coming soon

New mobile app launch

We are thrilled to introduce our brand-new, consolidated mobile application coming soon. Get ready to enjoy a smoother user experience, available soon in both the iOS and Google Play app stores.

Based on feedback from our users, the new app is designed with your needs in mind, offering:

- **Unified access:** Access to all your Micromedex subscriptions and all essential drug information from a single, comprehensive app
- **Improved navigation:** Enjoy a more intuitive interface for easy access to information
- **Ease of maintenance:** Experience automated updates so you can stay focused on your workflow

The following existing Micromedex mobile apps will now be available within one app:

- Drug Reference
- Drug Interaction
- IV Compatibility


We've also added more features for your convenience:

- Calculators
- Micromedex Assistant
- New accessibility features
- Advanced search experience
- Enhanced navigation

This is just our first step to enhancing our mobile experience. Additional releases will follow, including NeoFax® and Pediatrics reference information and additional navigation enhancements.

NOTE: The app is available at no charge for customers with respective online subscriptions of Micromedex. The original Micromedex mobile app will no longer be available for download 90 days after the new app is released.

Learn more about the new mobile app [here](#).



Improved visual experience for IV compatibility

A more responsive web design to support multiple screen sizes, from desktop to tablets to mobile phones to allow you improved use on all your devices will be available starting September 11th.

Now available - thanks to your feedback!

Even better navigation in drug monographs

In response to user feedback and usage analysis, we have enhanced the user experience, navigation, and organization of information within the drug monographs for faster access to critical data and decision points.

- **Access a preview:** you may have noticed a “New Look Preview” button on the Adult Dosing and Pediatric Dosing Quick Answer and In-Depth Answer sections that you can toggle on and off to preview an updated interface.
- **A collapsible view with clear headings:** when ‘on’, you will see the Dosing section content in a collapsed view, where the information will now be organized under ‘headings’ that you can click to expand for more details. There is also an ‘expand all’ capability if you want to view all information at once. The Dosing section updates, as well as other section updates throughout the monographs will soon be the default setting across the product.
- **Quicker, clearer access to content:** with a collapsed view, the monograph layout is cleaner and with headings that can be expanded to view the section you need most helping you identify content of interest more quickly.
- **View a demo [here](#)**

Use the New Look Preview to try out these changes in the system and familiarize yourself with the new look and feel. Whether you love it, like it, or want to see some changes, we encourage you to submit feedback via the button on the right-hand side of the screen. Your comments help impact the future product roadmap.

The image displays two side-by-side screenshots of the Merative Micromedex website for the drug Gabapentin, illustrating a user interface update. A large blue arrow points from the current view on the left to the 'New Look Preview' on the right.

Current View (Left): Shows the standard layout with a navigation bar at the top, a search bar, and a sidebar on the left containing a list of sections like 'Dosing/Administration', 'Medication Safety', and 'Contraindications'. The main content area is titled 'Gabapentin' and includes sections for 'Dosing/Administration' and 'Important Note'. A 'New Look Preview' button is visible in the top right corner.

New Look Preview (Right): Shows the updated interface. The sidebar is collapsed, and the main content area is more organized with clear headings. A 'Print' button is added to the top right. The 'New Look Preview' button is now a toggle switch, and a callout box indicates that users can 'Expand All' to view the entire section.

Enhanced user experience for IV Compatibility

We have made several important improvements to Micromedex IV Compatibility to help you make quick, accurate decisions at the point of care.

- **Chart view and list view:** Users now have two options for visualizing Micromedex IV Compatibility information. Chart view is the new default view offering healthcare professionals the ability to view and check the compatibility of one or multiple intravenous (IV) drugs at a glance and optimize medication administration timing, sequencing, and safety. Prefer the traditional list view? You can easily toggle to the list view.
- **Visual clarity:** Icons have been redesigned for easier results interpretation, and the expanded caution variable reminds users to verify the details before administering the drugs. Additionally, results are preset for Drug-Drug & Drug-Solution with the **Administration Method** set to Y-site and for all **Compatibility results**. The filters were selected based on the highest volume of conditions for visualizing IV Compatibility.
- **Most searched drug pairs:** This feature accelerates the speed of answering by providing frequently searched drug combinations in one click.
- **Updated IV Single workflow:** IV Compatibility (single) now opens within the IV Compatibility tool and auto-populates the drug name from the monograph.

Watch a demo [here](#), download a Quick Reference Guide [here](#) and the education slide deck [here](#). All these materials to educate your teams are also available on the [training center](#).

The screenshot displays the Merative Micromedex IV Compatibility interface. At the top, there is a navigation bar with options like Home, Drug Interactions, IV Compatibility (selected), Drug ID, Drug Comparison, CareNotes, Neofax®/Pediatrics, Tox & Drug Product Lookup, RED BOOK, Calculators, and Formulary. A search bar is located on the right. Below the navigation bar, the page title is "IV Compatibility Results - Chart view". On the left side, there are several filter panels: "Preparation and Storage" (listing ceftRIAXone sodium, Potassium Chloride, and Vancomycin Hydrochloride), "Filter results" (with sub-sections for Administration Method: Y-Site, Admixture, Syringe; and Compatibility: Compatible, Incompatible, Uncertain, No Data), and "Drugs" (set to All (3)). The main content area shows a table of drug compatibility results for three drugs: ceftRIAXone sodium, Potassium Chloride, and Vancomycin Hydrochloride. The table has columns for each drug and rows for each drug combination. Results are shown as "Y-Site" with icons indicating the number of results: green for compatible, red for incompatible, and blue for uncertain. For example, ceftRIAXone sodium and Potassium Chloride have 4 compatible results. A "Variable Results" warning icon is present in the top right corner. At the bottom right, there is a "Micromedex Assistant" button. The footer contains a disclaimer: "Powered by Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility). IV Index contains the Confidential Information of BAXTER HEALTHCARE CORPORATION. Use of IV Index or information which it contains by anyone other than an expressed licensee is strictly prohibited."

Expanded pediatric content

The pediatric content within the NeoFax and Pediatrics solution has been expanded and enriched through a targeted review of over 600 drugs with updates and additions for 300+ pediatric drug monographs.

The content expansion was based on a body systems and clinical conditions approach and backed by rigorous reviews of clinical studies, metanalyses, guidelines, and FDA updates.

Explore this expanded content within the NeoFax and Pediatrics solution, available in Micromedex, DynaMedex, or our mobile apps.

Updates to RED BOOK content to support ease of use and patient safety

Enhancements have been made to RED BOOK to improve clinical relevancy:

- Significant Omissions, characteristics a manufacturer chooses to identify in their labeling as having been omitted from a product, are no longer abbreviated and now spelled out entirely to provide additional clarity to those with allergies, dietary concerns, or other avoidance needs.
- Active ingredients and strengths are now available in clinically relevant order instead of alphabetical order.
- For the integrated version of RED BOOK, the Script ID field has been replaced by a new clinically relevant data table, and spacing will be consistent with other deliverables.

Ongoing

Off-label dosing

Our editors are currently engaged in an extensive review of existing off-label indications to evaluate and add corresponding dosing recommendations and expanded evidence where appropriate to bring additional value. Visit the Content Update Highlights section of the Latest News on the Micromedex home page to view selected off-label dosing indication additions.

Medication conversions

An editorial initiative is addressing the addition or updating of recommendations on perioperative medication management, deprescribing, or transitioning between therapies. Editors have addressed 14 classes, primarily perioperative recommendations for behavioral health, neurology, and anticoagulant drugs. Examples include citalopram, levetiracetam and rivaroxaban, and content can be found in Quick Answers -> Adult Dosing -> General Dosage Information.

Patient education

Patient education titles related to idiopathic overactive bladder, acne, breast cancer screening, hypertrophic cardiomyopathy, peripheral artery disease, fall prevention, fecal incontinence, Barrett's esophagus, and tuberculosis have been revised/updated based on the following guidelines:

- AUA/SUFU Guidelines on the Diagnosis and Treatment of Idiopathic Overactive Bladder
- AAD Guideline on the Management of Acne Vulgaris
- Screening for Breast Cancer: US Preventative Services Task Force Recommendation Statement
- AHA/ACC GL for the Management of Hypertrophic Cardiomyopathy
- AHA/ACC GL for the Management of Lower Extremity Peripheral Artery Disease
- USPSTF GL on Interventions to Prevent Falls in Community-Dwelling Older Adults
- ASCRS GL for the Management of Fecal Incontinence
- AGA GL on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia
- WHO GL on Tuberculosis

Toxicology

In response to requests from America's Poison Centers, the Poisindex Products team added 80 new mushroom "wellness products" to our database. This allows poison centers to granularly track and code exposures to these potentially harmful products claiming to have similar psychoactive effects as psilocybin and amanita mushrooms.

What would you like to see next?

If there are additional features you would like to see added to Micromedex, please let us know by telling your account representative or by submitting feedback directly within the product on the right-hand side of your screen through the feedback button.

News you can use

Six ways that Micromedex supports patient safety

Clinicians and healthcare teams are dedicated to providing safe and effective care, yet the complexity of today's health landscape poses significant challenges.

Micromedex clinical decision support is a vital tool in navigating these complexities, helping to reduce medication-related harm and enhance patient safety. View the infographic to see six key ways that Micromedex supports safe patient care, from medication safety, to support in critical situations and for specialty populations, and more.

View the infographic →

Training resources and news

Have you checked out our most valuable training videos on the [Micromedex training center](#)? View resources by role, tools, or application.

The latest materials in the training center include [a new scenario-based tutorial video for the IV Compatibility tool](#), to guide you through how to use it, including the recently enhanced chart view.

Looking for customized training for you or your team? Reach out to your Customer Service Manager or [email us](#).

Look out for the new clinical tips and tricks!

In the Latest News section of Micromedex online you will find monthly **Clinical Challenges** (short multiple-choice quizzes) and regular top tips for users in the **Did You Know** series.

Collaborating for additional enhancements

Micromedex proudly partners with EBSCO Information Services to offer [DynaMedex](#), the all-in-one resource for evidence-based decision support that brings together two award-winning solutions: medication insights from Micromedex plus disease and condition management from DynaMed.

We continue to collaborate on further enhancements, including seamlessly integrating new technologies such as generative artificial intelligence through responsible use. Learn more about the latest developments at the [Innovation Center](#).

Further reading

Take a look at some of our recent topic-focused publications:



Tackling medication errors: the global challenge of preventing medication-related harm for safer care - [Read now](#)



Hot topic: the emerging threat of microdosing chocolate bars and the critical role of Poison Centers in protecting public health - [Read now](#)



Patient safety insights: considerations for polypharmacy and avoidable harm in elderly patients - [Read now](#)



A tool for safe, effective care: six ways that Micromedex supports patient safety - [Read now](#)

Bookmark the thought leadership site

Take a look at the Micromedex web page for thoughtful insights on focused topics of interest to support wider reading and exchange of knowledge. Check out the current topics on the new page:

[View the page](#)



Follow Micromedex on LinkedIn

Make sure you see the latest topic-focused publications and product updates on the [LinkedIn page](#).

Upcoming activities and events

Stop by our booth and talk with the team at these upcoming events:

- NACCT: Sept 19-23, Denver
- HCP Fall: Sept 30-Oct 2, Columbus
- Expopharm: Oct 9-12, Munich
- Frankfurt Book Fair: Oct 16-20, Frankfurt
- Global Health Exhibition and Conference: Oct 21-23, Riyadh
- National Pharmacovigilance Conference: Nov 12-14, Oviedo
- Korean Society of Health System Pharmacists Fall conference: Nov 23, Seoul
- CAMCAR: Dec 4, Panama City
- ASHP Mid-Year: Dec 8-12, New Orleans

If you have any questions, contact your local representative or [contact us](#) via the website.

Stay in the know

We would like to make sure that all Micromedex users have access to the newsletters to stay current on the latest product enhancements, training resources, publications and upcoming events. We invite you to share this newsletter with your teams, and if this was shared with you, subscribe to make sure you don't miss future updates.

Subscribe to Micromedex communications →